1 / 6

Process design for the production of Fab fragment for therapy

Process design for the production of Fab fragment for therapy. Group 6 Shiang -Yuan Hsieh, Yun-Hsuan Liu, Chao-Ming Yen. Antibody therapy. Bevacizumab v.s Ranibizumab. Anti- angiogenic drugs: block the formation of new blood v essels to inhibit tumor growth

giles
Download Presentation

Process design for the production of Fab fragment for therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Process design for the production of Fab fragment for therapy Group 6 Shiang-Yuan Hsieh, Yun-Hsuan Liu, Chao-Ming Yen

  2. Antibody therapy

  3. Bevacizumabv.sRanibizumab • Anti-angiogenic drugs: block the formation of new blood vessels to inhibit tumor growth • By targeting and inhibiting the function of a natural protein called vascular endothelial growth factor (VEGF) • The whole antibody versus a antibody fragment

  4. Antibody • Also called immunoglobulins (Ig) that used by immune system. • Five classes of Ig: IgA, IgE, IgG, IgD, IgM.

  5. Fragment antigen binding(Fab fragment) • A region on an antibody which binds to antigens • Composed of one constant and one variable domain of each of the heavy and the light chain

  6. Why make Fab Fragments? • Smaller size that can promote the efficiency of penetration of tissue section. • Reduce nonspecific binding that results from Fc interactions. • Potentially higher sensitivity in antigen. • Reduce the risks from immune response. • Production is more economical.

More Related